Three Phase 3 Trials, Three Decisions to Measure Steroid-Toxicity Directly
Patients on long-term steroids for autoimmune and inflammatory diseases know the damage that these drugs cause. The question for sponsors has long been whether a trial can prove it. In June 2026, ...
Secukinumab Delivers Sustained Remission and Toxicity Reduction in PMR
For the majority of patients with polymyalgia rheumatica, glucocorticoids do not provide a durable solution. They induce remission, but they do not maintain it. REPLENISH, the largest PMR clinical ...
Study Highlights Significant Unmet Needs of Polymyalgia Rheumatica Patients
Results from a Phase 3 clinical trial reported in The New England Journal of Medicine,[1] have highlighted the significant unmet need for effective long-term treatments for those battling polymyalgia ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
